Addition of pembrolizumab to chemotherapy extends survival in advanced lung cancer
Introducing first-line immunotherapy could benefit long-term outcomes in advanced non-small-cell lung cancer (NSCLC), a study has revealed.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study